Cypre
Cypre is a privately held San Francisco biotech developing novel 3D in vitro tumor microenvironment models to support cancer drug discovery. Founded in 2016, the company operates with 1-10 employees and has no disclosed commercial activity.
- Company typePrivate
- Founded2016
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Cypre firmographics
Firmographics- Name
- Cypre
- Website
- https://cypre.co
- Company type
- Private
- Founded year
- 2016
- Headcount range
- 1–10 employees
- Short description
- Cypre is a privately held San Francisco biotech developing novel 3D in vitro tumor microenvironment models to support cancer drug discovery. Founded in 2016, the company operates with 1-10 employees and has no disclosed commercial activity.
- Ownership category
- akta.pro rank
Cypre industry classification
Industry- Product category
- Oncology Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Cypre is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Cypre business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Cypre product offering
Product offeringCore offering
Cypre develops novel 3D in vitro models that recapitulate the tumor microenvironment and uses them to support cancer drug discovery. The company provides preclinical oncology research tools and services designed to better predict therapeutic response than conventional 2D cell culture systems. Its offerings target pharmaceutical and biotechnology customers engaged in oncology drug development.
Differentiator
Problem solved
Functional benefit
Products and services
- 3D In Vitro Tumor Microenvironment (TME) Models Proprietary 3D in vitro models that recreate the tumor microenvironment for cancer drug discovery, offered to pharmaceutical and biotechnology customers for preclinical oncology research and therapeutic screening.
- Cancer Drug Discovery Services Applied research services applying Cypre's 3D tumor microenvironment models to customer oncology drug discovery programs, including assay design, compound screening, and translational biology support.
Companies that use Cypre
Customer profileIdeal customer profiles2 records
Cypre technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cypre competitors and assessment
Company assessmentDirect peers
- Mimetas: Mimetas provides microfluidic 3D tissue models, including tumor and organ-on-chip assays, serving pharma R&D with overlapping use cases to Cypre's 3D TME models.
- Emulate: Emulate develops organ-on-chip platforms including tumor models for preclinical drug testing, directly competing with Cypre's 3D in vitro TME thesis for pharma discovery customers.
- InSphero: InSphero offers 3D spheroid and organoid models including tumor microtissues for drug discovery, a directly comparable 3D in vitro preclinical platform.
Broad incumbents
- Crown Bioscience: Crown Bioscience is a large preclinical CRO offering patient-derived xenografts and 3D tumor models, broadly competing for the same pharma oncology discovery budget as Cypre.
- Champions Oncology: Champions Oncology provides patient-derived tumor models and preclinical oncology services, an established incumbent in the same translational oncology discovery space as Cypre.
- Molecular Devices: Molecular Devices supplies 3D cell culture and high-content imaging instrumentation widely used to read out tumor model assays, an adjacent incumbent whose customers overlap Cypre's pharma end users.
Emerging players
- Organoid Therapeutics: Organoid Therapeutics develops tumor organoid platforms for cancer drug discovery and translational research, an emerging niche player with overlapping 3D in vitro methodology.
- SynVivo: SynVivo builds microfluidic organ-on-chip tumor models for drug screening, a smaller-scale player in the same 3D in vitro tumor modeling niche as Cypre.
Market position
Customer concentration
Cypre social profiles
Digital presenceCypre financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cypre leadership team
Management profileNumber of profiles
Profiles2 records
Cypre funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cypre M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cypre
What does Cypre do?
Cypre develops novel 3D in vitro models that recapitulate the tumor microenvironment and uses them to support cancer drug discovery. The company provides preclinical oncology research tools and services designed to better predict therapeutic response than conventional 2D cell culture systems. Its offerings target pharmaceutical and biotechnology customers engaged in oncology drug development.
When was Cypre founded?
Cypre was founded in 2016. It employs 1 to 10 people.
Where is Cypre based?
Cypre is headquartered in San Francisco, United States, in the North America region.
Who are Cypre's main competitors?
Direct peers on record are Mimetas, Emulate and InSphero. Broad incumbents are Crown Bioscience, Champions Oncology and Molecular Devices. Emerging players are Organoid Therapeutics and SynVivo.
Does Cypre have an API?
No public API is recorded for Cypre.
What industry is Cypre in?
Cypre's product category is Oncology Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.